(Q38889516)

English

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Teresa Di Desidero

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Christopher Jedeszko

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Marta Paez-Ribes

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Shan Man

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Christina R Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Ping Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Georg A Bjarnason

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Guido Bocci

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Robert S Kerbel

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

1 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Science Translational Medicine

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

282

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

282ra50

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Treatment selection in metastatic renal cell carcinoma: expert consensus

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Resistance to targeted therapy in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Practices and pitfalls of mouse cancer models in drug discovery.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Mouse models of advanced spontaneous metastasis for experimental therapeutics

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

What's wrong with our cancer models?

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Development of a preclinical model of spontaneous human melanoma central nervous system metastasis

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Future directions in renal cell carcinoma: 2011 and beyond

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

In vitro cultivation of human renal cell cancer. II. Characterization of cell lines

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Identifiers

10.1126/SCITRANSLMED.3010722

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38889516&oldid=1794068795"